Epizyme Inc

Epizyme — J.P. Morgan 2017 Healthcare Conference

31 slides from Epizyme's conference presentation, Jan 9, 2017

  1. Slide 1: Epizyme Corporate Presentation, J.P. Morgan 2017 Healthcare Conference

    Slide 1: Epizyme Corporate Presentation, J.P. Morgan 2017 Healthcare Conference

    Epizyme Corporate Presentation J.P. Morgan 2017 Healthcare Conference REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES Presentation as of January 8, 2017 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    regulatory review or approval process; expectations for regulatory approvals to conduct trials or to market products; whether the Company’s cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters tha

  3. Slide 3: Epizyme: Leader in Targeted Epigenetic Drug Discovery & Development

    Slide 3: Epizyme: Leader in Targeted Epigenetic Drug Discovery & Development

    PROOF-OF-CONCEPT with tazemetostat in hematologic malignancies and solid tumors BROAD DEVELOPMENT as mono and combo therapy; in front- and late-line settings 2018 target launch for tazemetostat in first indication FINANCIAL STRENGTH PIONEERING discovery platform for next generation of epigenetic pro

  4. Slide 4: Rewriting Cancer Treatment Through Targeted Epigenetic Medicines

    Slide 4: Rewriting Cancer Treatment Through Targeted Epigenetic Medicines

    REWRITING CANCER TREATMENT THROUGH TARGETED EPIGENETIC MEDICINES launch tazemetostat globally maximize tazemetostat value advance 3 new programs into clinical trials extend epigenetic leadership

  5. Slide 5: Advancing a Leading Epigenetic Pipeline

    Slide 5: Advancing a Leading Epigenetic Pipeline

    ADVANCING A LEADING EPIGENETIC PIPELINE PROGRAM STUDY RESEARCH PHASE 1 PHASE 2 TAZEMETOSTAT 1 Molecularly Defined Solid Tumors Monotherapy in adults (5-arm) Dose-escalation and expansion in pediatrics Non-Hodgkin Lymphoma Monotherapy in relapsed/refractory DLBCL & FL Prednisolone combination in rela

  6. Slide 6: Tazemetostat: Most Advanced EZH2 Inhibitor

    Slide 6: Tazemetostat: Most Advanced EZH2 Inhibitor

    TAZEMETOSTAT: MOST ADVANCED EZH2 INHIBITOR POTENT AND SELECTIVE SMALL MOLECULE FAVORABLE SAFETY PROFILE CONVENIENT ORAL DOSING HEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS MONOTHERAPY AND COMBINATION POTENTIAL COMPREHENSIVE IP ESTATE THROUGH AT LEAST 2032 EXCLUSIVE GLOBAL RIGHTS OUTSIDE OF JAPAN

  7. Slide 7: EZH2 Plays Critical Role in Broad Range of Cancers

    Slide 7: EZH2 Plays Critical Role in Broad Range of Cancers

    EZH2 PLAYS CRITICAL ROLE IN BROAD RANGE OF CANCERS …allowing proliferation of cancer cells Genetic lesions in EZH2 and related genes found in many forms of cancer EZH2 activating mutations Loss of function in proteins that oppose EZH2 function (e.g., INI1) EZH2: enzymatic component of the Polycomb R

  8. Slide 8: Targeting EZH2 for Both Solid Tumors and Hematological Malignancies

    Slide 8: Targeting EZH2 for Both Solid Tumors and Hematological Malignancies

    TARGETING EZH2 FOR BOTH SOLID TUMORS AND HEMATOLOGICAL MALIGNANCIES EZH2 BIOLOGICAL ACTIVITY IMPLICATED IN BROAD RANGE OF CANCERS

  9. Slide 9: Tazemetostat for Molecularly Defined Solid Tumors

    Slide 9: Tazemetostat for Molecularly Defined Solid Tumors

    TAZEMETOSTAT FOR MOLECULARLY DEFINED SOLID TUMORS

  10. Slide 10: INI1-Negative Tumors: No Targeted Treatment Options

    Slide 10: INI1-Negative Tumors: No Targeted Treatment Options

    INI1-NEGATIVE TUMORS: MOLECULARLY DEFINED TUMORS WITH NO TARGETED TREATMENT OPTIONS Poor prognosis and high mortality rates US, EU, Japan annual incidence of ~2,000 patients1 Current standard-of-care is surgical resection with or without radiation Limited effectiveness of chemotherapy; short duratio

  11. Slide 11: Clinical Proof-of-Concept in INI1-Negative Tumors Established in Phase 1

    Slide 11: Clinical Proof-of-Concept in INI1-Negative Tumors Established in Phase 1

    CLINICAL PROOF-OF-CONCEPT IN INI1-NEGATIVE TUMORS ESTABLISHED IN PHASE 1 STUDY Consistent with preclinical hypothesis of INI1-negative tumor sensitivity to EZH2 inhibition with tazemetostat 7 patients with INI1- and SMARCA4-negative tumors had either meaningful reduction in tumor volume or achieved

  12. Slide 12: Preparing for Data in Phase 2 Study in Adults with INI1-Negative Tumors

    Slide 12: Preparing for Data in Phase 2 Study in Adults with INI1-Negative Tumors

    Primary endpoints: Composite including objective response rate (ORR) for epithelioid sarcoma; ORR for rhabdoid and other INI1-negative tumors Phase 2 data presentation planned for 2Q 2017; Regulatory engagement planned for mid-2017 Global Phase 2 Study in 5 Cohorts (dose: 800mg BID) PREPARING FOR DA

  13. Slide 13: Tazemetostat Study Underway in Children with INI1-Negative Tumors

    Slide 13: Tazemetostat Study Underway in Children with INI1-Negative Tumors

    TAZEMETOSTAT STUDY UNDERWAY IN CHILDREN WITH INI1-NEGATIVE TUMORS CNS rhabdoid tumors Ex-CNS rhabdoid tumors Primary endpoints: Safety, determine recommended Phase 2 dose FDA Pediatric ODAC provided positive feedback and support on study Secondary endpoints: ORR, duration of response, PFS, OS, PK Do

  14. Slide 14: Mesothelioma: Aggressive and Rare Solid Tumor

    Slide 14: Mesothelioma: Aggressive and Rare Solid Tumor

    MESOTHELIOMA: AGGRESSIVE AND RARE SOLID TUMOR GLOBAL PHASE 2 MONOTHERAPY TRIAL UNDERWAY 67 patients with relapsed/refractory mesothelioma Part 1: safety and PK in patients regardless of BAP1 status (n=12) Part 2: disease control rate in BAP1 loss-of-function patients (2-stage with imbedded futility;

  15. Slide 15: Tazemetostat Treatment for Non-Hodgkin Lymphoma

    Slide 15: Tazemetostat Treatment for Non-Hodgkin Lymphoma

    TAZEMETOSTAT TREAMENT FOR NON-HODGKIN LYMPHOMA

  16. Slide 16: Broad Tazemetostat Development Strategy in Non-Hodgkin Lymphoma

    Slide 16: Broad Tazemetostat Development Strategy in Non-Hodgkin Lymphoma

    MONOTHERAPY COMBINATION DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Front-line combination with R-CHOP Relapsed/refractory Phase 2 study in DLBCL R/R combination with Tecentriq® R/R combination with prednisolone (planned 1Q17 initiation) Relapsed/refractory Phase 2 study in FL New combination TBD (planned

  17. Slide 17: NHL: Top Diagnosed Cancer and Growing

    Slide 17: NHL: Top Diagnosed Cancer and Growing

    NHL: TOP 10 DIAGNOSED CANCER AND GROWING1 40-50% of all DLBCL patients relapse4 ~20% of GCB DLBCL & FL tumors harbor EZH2 activating mutations3 NEED for new treatments for relapsed/refractory NHL INCURABLE follicular lymphoma as a disease today5 NO front-line advancements in standard-of-care for DLB

  18. Slide 18: NHL: Top 10 Diagnosed Cancer and Growing

    Slide 18: NHL: Top 10 Diagnosed Cancer and Growing

    Front-line DLBCL (~50,000) Estimated Number of US and EU5 DLBCL drug-treated patients in 20172 Estimated Number of US and EU5 FL drug-treated patients in 20172 Front-line FL (~25,000) NHL: TOP 10 DIAGNOSED CANCER AND GROWING1 Patients with EZH2 mutations may represent fastest path to market in NHL D

  19. Slide 19: Tazemetostat Proof-of-Concept in NHL in Phase 1

    Slide 19: Tazemetostat Proof-of-Concept in NHL in Phase 1

    TAZEMETOSTAT PROOF-OF-CONCEPT IN NHL IN PHASE 1 All 3 patients with CRs still in CR and on treatment (out ~2.5 years) Promising anti-tumor activity and favorable safety profile Meaningful PFS observed in patients responding to tazemetostat Data as of 5/27/16 Ribrag et al., ASH Lymphoma 2016 Food Eff

  20. Slide 20: Encouraging Early Activity in Phase 2 NHL Study

    Slide 20: Encouraging Early Activity in Phase 2 NHL Study

    Data as of 5/27/16 Morschhauser et al., ASH Lymphoma 2016 *Patients classified by histology and EZH2 mutation status only n.r.: not reported Does not include two evaluable patients, previously reported as DLBCL wt (one SD and one PD) who will be reclassified based on ctDNA ENCOURAGING EARLY ACTIVITY

  21. Slide 21: Preparing for Data & Regulatory Engagement in 2017

    Slide 21: Preparing for Data & Regulatory Engagement in 2017

    Efficacy Evaluation as of ASH Lymphoma Biology Cell of Origin Reclassification by Nanostring 30% study enrollment Cohort* Evaluable Pts CR PR SD PD Response Rate (Eval. pts) DLBCL EZH2 Mutant 7 0 3 2 2 43% DLBCL EZH2 Wild-Type1 35 4 3 10 18 20% FL EZH2 Mutant 3 0 3 0 0 100% FL EZH2 Wild-Type n.r. n.

  22. Slide 22: Generally Well-Tolerated with Infrequent Grade ≥3 Adverse Events

    Slide 22: Generally Well-Tolerated with Infrequent Grade ≥3 Adverse Events

    Generally well-tolerated with infrequent grade ≥3 adverse events All Adverse Events (AEs)* Treatment-Related AEs Patients (n=82) with AE¹ All Grades Grade ≥ 3 All Grades Grade ≥ 3 Nausea 15 (18%) 0 11 (13%) 0 Cough 11 (13%) 0 1 ( 1%) 0 Asthenia 9 (11%) 0 8 (10%) 0 Thrombocytopenia 9 (11%) 3 ( 4%) 7

  23. Slide 23: Exploring Tazemetostat in Immuno-Oncology Combination

    Slide 23: Exploring Tazemetostat in Immuno-Oncology Combination

    EZH2 inhibition enhances activity of checkpoint inhibitors in preclinical models Global Phase 1b study with Tecentriq® (atezolizumab), only approved anti-PD-L1 cancer immunotherapy ~45 patients with relapsed/refractory DLBCL Primary endpoints: safety, combination tolerability and establish recommend

  24. Slide 24: Advancing Tazemetostat in Front-Line Combination

    Slide 24: Advancing Tazemetostat in Front-Line Combination

    Preclinical evidence demonstrates synergy between tazemetostat and R-CHOP Phase 1b/2 study as front-line treatment with R-CHOP, standard-of-care for DLBCL Up to 133 newly diagnosed, elderly high-risk patients with DLBCL Primary efficacy endpoint: complete response rate Secondary endpoints: ORR and P

  25. Slide 25: Expanding Tazemetostat in Steroid Combination in 2017

    Slide 25: Expanding Tazemetostat in Steroid Combination in 2017

    EXPANDING TAZEMETOSTAT IN STEROID COMBINATION IN 2017 Tazemetostat proliferation IC50 as a function of prednisolone concentration Strong tazemetostat synergy with prednisolone demonstrated in preclinical models Clinical study of tazemetostat in combination with prednisolone Evaluate combination in R

  26. Slide 26: Well-Positioned for Success

    Slide 26: Well-Positioned for Success

    WELL-POSITIONED FOR SUCCESS

  27. Slide 27: Targeting New Programs in Clinical Development by Year-End 2020

    Slide 27: Targeting New Programs in Clinical Development by Year-End 2020

    TARGETING 3 NEW PROGRAMS IN CLINICAL DEVELOPMENT BY YEAR-END 2020 DIFFERENTIATED RESEARCH PLATFORM TO CREATE NEXT GENERATION OF TARGETED EPIGENETIC MEDICINES

  28. Slide 28: Strategic Collaborations Support Pipeline Advancement

    Slide 28: Strategic Collaborations Support Pipeline Advancement

    STRATEGIC COLLABORATIONS SUPPORT PIPELINE ADVANCEMENT Epizyme A PARTNER-OF-CHOICE FOR EPIGENETIC DRUG DISCOVERY AND DEVELOPMENT

  29. Slide 29: Financial Strength to Deliver on Our Goals

    Slide 29: Financial Strength to Deliver on Our Goals

    FINANCIAL STRENGTH TO DELIVER ON OUR GOALS Significant funding from collaboration agreements and potential future milestones ($208M of non-equity funding to date) Cash and securities of $263M as of 3Q 2016 58M shares outstanding No debt Runway to fund operations into at least 3Q18

  30. Slide 30: 2017: A Transformational Year for Epizyme

    Slide 30: 2017: A Transformational Year for Epizyme

    TECENTRIQ® R/R COMBO Determine recommended Phase 2 dose and advance study Phase 2 ADULT INI1-NEG TUMORS Complete enrollment in ES cohort Successfully present Phase 2 data Engage with regulatory authorities on registration pathways FRONT-LINE R-CHOP COMBO Determine recommended Phase 2 dose Advance in

  31. Slide 31

    Slide 31

Source: SEC EDGAR · 8-K filed Jan 9, 2017

More decks from Epizyme Inc